Bob
Senior Member
- Messages
- 16,455
- Location
- England (south coast)
Below are the details of a report in the new 2016 conference version of Invest in ME's journal. The report starts on page 46.
The report details an interesting biomedical study, being carried out in New Zealand, involving proteomics, cytokines and miRNAs. It sounds fascinating.
Invest in ME - The Journal of IiMER 2016
http://www.investinme.org/Documents/Journals/Journal of IiME Vol 10 Issue 1.pdf
Extract from the report:
Forum discussion thread for the journal:
http://forums.phoenixrising.me/inde...journal-of-iimer-2016-conference-no-11.45036/
.
The report details an interesting biomedical study, being carried out in New Zealand, involving proteomics, cytokines and miRNAs. It sounds fascinating.
Invest in ME - The Journal of IiMER 2016
http://www.investinme.org/Documents/Journals/Journal of IiME Vol 10 Issue 1.pdf
Tackling ME/CFS in New Zealand by the Principles of Precision Medicine
Warren P. Tate, Eiren C. Sweetman, Alex J. K. Noble, Christina D. Edgar, Grace Bateman, Angus Mackay, Margaret M. Ryan, Lynette D. Hodges & Rosamund Vallings.
Extract from the report:
In line with these concepts, we are now in the data collection stage for two small pilot studies, each with 10 patients, recruited in two separate regions of New Zealand. They are matched by age/gender with healthy controls, with one of the studies having a comparative cohort of multiple sclerosis (MS) patients, as an example of a ‘fatigue illness’ distinct from ME/CFS. Our goal is to examine and correlate changes in plasma cytokines and miRNAs, with the cellular transcriptome, and the proteome in purified immune cells. In the second study we are planning to link these molecular analyses to an exercise regime that measures physiological parameters before and after exercise. These two pilot studies in turn are preliminary to a planned larger study with 40 carefully evaluated patients from Dr Vallings health practice.
To understand the disease mechanism of ME/CFS in our NZ cohort at a molecular level, a comprehensive analysis has been undertaken in an initial pilot study group. Peripheral blood samples were taken from the study participants and plasma, lymphocytes and neutrophils extracted. From the plasma and lymphocyte immune cells total RNA (including small RNAs) was isolated using a mirVana™ PARIS™ RNA and Native Protein Purification Kit. Total protein was also obtained from the lymphocyte and neutrophil cells for western and proteome analysis. So far we have obtained and analysed data on both cytokines and microRNAs from plasma in one of our pilot studies, and are awaiting the results of analyses on the transcriptome encompassing coding, small and large noncoding RNAs, and initiating a study of the proteome.
The study is supported by ANZMES. The Associated New Zealand ME Society Inc, Auckland, New Zealand. http://www.anzmes.org.nzAcknowledgements: We are grateful for support from ANZMES the national ME/CFS group of New Zealand, Lottery Health Fund of New Zealand, H S and J C Anderson Charitable Trust, a private bequest.
Forum discussion thread for the journal:
http://forums.phoenixrising.me/inde...journal-of-iimer-2016-conference-no-11.45036/
.
Last edited: